10-Q: Astrana Health Q3 2025: Revenue Soars 100% Amid Prospect Acquisition

Astrana Health, Inc. reported a significant 100% increase in total revenue for Q3 2025, reaching $956.0 million, primarily driven by the acquisition of Prospect Medical Holdings, Inc., despite a substantial drop in net income.

Summary

• Total revenue for the three months ended September 30, 2025, increased 100% to $956.0 million from $478.7 million in the same period of 2024.
• Total revenue for the nine months ended September 30, 2025, increased 63% to $2,231.2 million from $1,369.3 million in the same period of 2024.
• The acquisition of Prospect Medical Holdings, Inc. contributed approximately $308.0 million to revenue from its acquisition date of July 1, 2025.
• Net income attributable to Astrana Health, Inc. for Q3 2025 decreased 98% to $0.4 million from $16.1 million in Q3 2024.
• Net income attributable to Astrana Health, Inc. for the nine months ended September 30, 2025, decreased 67% to $16.5 million from $50.1 million in the same period of 2024.
• Adjusted EBITDA for Q3 2025 increased 51.6% to $68.5 million from $45.2 million in Q3 2024.
• Adjusted EBITDA for the nine months ended September 30, 2025, increased 13% to $153.0 million from $135.3 million in the same period of 2024.
• The company managed over 1.6 million patients as of September 30, 2025, an increase from approximately 1.0 million as of September 30, 2024.
• A $13.0 million charge was recorded in Q3 2025 for a legal matter related to an arbitration proceeding with a provider associated with CFC Health Plan, Inc.
• Long-term debt, net, increased to $1,002.0 million as of September 30, 2025, from $425.3 million as of December 31, 2024, primarily to finance the Prospect acquisition.

Sentiment

Score: 4

Explanation: While revenue growth and Adjusted EBITDA were strong due to the Prospect acquisition, the significant decline in net income, increased operating expenses, and a substantial legal contingency charge indicate underlying challenges. The increased debt load and regulatory risks also contribute to a cautious outlook.

Positives

• Significant revenue growth: Total revenue increased 100% in Q3 2025 and 63% for the nine months, largely due to strategic acquisitions.
• Successful integration of Prospect acquisition: Contributed $308.0 million in revenue and expanded the provider network by over 11,000 providers, enhancing access, quality, and value.
• Increased patient base: Managed over 1.6 million patients as of September 30, 2025, a substantial increase from 1.0 million in the prior year.
• Adjusted EBITDA growth: Increased 51.6% in Q3 2025 to $68.5 million and 13% for the nine months to $153.0 million, indicating improved operational performance excluding certain non-cash and non-recurring items.
• Strong liquidity: Believes it has sufficient liquidity to fund operations for at least the next 12 months and the foreseeable future, with cash and cash equivalents at $462.2 million.
• Strategic debt management: Entered into an interest rate swap agreement for $200 million of debt at a fixed rate of 3.179% to manage interest rate risk.
• Care Enablement segment operating income increased 271% in Q3 2025 to $23.4 million and 72% for the nine months to $28.8 million, driven by managing more IPAs and the Prospect acquisition.

Negatives

• Significant decline in net income: Net income attributable to Astrana Health, Inc. decreased 98% in Q3 2025 to $0.4 million and 67% for the nine months to $16.5 million.
• Increased operating expenses: Cost of services, general and administrative expenses, and depreciation and amortization all significantly increased due to acquisitions and operational growth.
• Higher interest expense: Increased 100% in Q3 2025 to $17.7 million and 29% for the nine months to $32.4 million due to increased borrowings for the Prospect acquisition.
• Legal contingency charge: Recorded a $13.0 million charge in Q3 2025 for an arbitration proceeding related to CFC Health Plan, Inc.
• Care Partners segment operating income decreased 35% in Q3 2025 to $25.3 million and 3% for the nine months to $119.2 million, primarily due to the $13.0 million loss contingency.
• Care Delivery segment operating loss increased 961% for the nine months to $2.0 million, attributable to an increase in expenses incurred related to newer clinic locations.
• Decrease in interest income: Down 7% in Q3 2025 to $3.5 million and 28% for the nine months to $8.2 million due to a decrease in cash held in interest-bearing bank accounts.
• Other income (loss) significantly decreased/turned to loss: Primarily due to debt issuance costs expensed and lack of similar gains from promissory note extinguishment or related party reimbursements seen in the prior year.

Risks

• The One Big Beautiful Bill Act (OBBBA), enacted July 4, 2025, introduces Medicaid work-requirement pilots and tighter provider-tax rules beginning in 2026, which could reduce patient population and managed care enrollees due to stricter eligibility requirements (e.g., work/community service, copayments, immigration enforcement).
• Loss of Medicaid benefits due to OBBBA may result in higher uncompensated emergency admissions of uninsured individuals at Foothill Regional Medical Center (FRMC), acquired in the Prospect Acquisition.
• Medicaid provider tax reform, targeted by the current administration to reduce federal Medicaid spending, could adversely impact FRMC revenues, potentially forcing hospital service reductions or closures.
• The bankruptcy filing of Prospect PhysicianCo Entities on July 7, 2025, could lead to breaches or noncompliance with contractual obligations under the asset sale transaction.
• Limited to no recourse against the bankrupt Prospect PhysicianCo Entities for potential breaches, due to their bankruptcy filing, elimination of an escrow account for non-assumed liabilities, and elimination of recourse (with certain exceptions) per the July 1, 2025 letter agreement.
• Legal proceedings are inherently uncertain, and while current liabilities are not expected to have a material adverse effect, the outcome of a particular matter or a combination of matters could materially impact results of operations.
• Cannot be certain that liability insurance coverage will be adequate to cover future claims, and annual renewal of claims-made policies may not be available at acceptable costs and on favorable terms.
• Financial statements rely on management's estimates and assumptions (e.g., collectability of receivables, medical liabilities, goodwill valuation), and actual results could differ materially.
• The operations of Prospect are excluded from the evaluation of internal control over financial reporting in the first year of consolidation, meaning potential control weaknesses in Prospect's operations are not yet fully assessed.

Future Outlook

The company anticipates that the One Big Beautiful Bill Act (OBBBA) will reduce federal and state income tax payables in the current year but will not materially impact tax expenses or benefits. Management believes Astrana is well-positioned to navigate potential changes from OBBBA, such as Medicaid work-requirement pilots and tighter provider-tax rules, due to its diversified footprint, strong Medicaid performance, and care-enablement infrastructure. The company expects to maintain continuity of care and support state partners through policy transitions.

Management Comments

• "We believe Astrana is well-positioned to navigate these changes and view these headwinds as manageable."
• "Our diversified footprint, strong track record of Medicaid performance, and investment in care-enablement infrastructure provide meaningful insulation."
• "We remain focused on maintaining continuity of care and supporting our state partners through this policy transition."
• "The acquisition significantly expanded the Company's provider network and enhanced our ability to offer increased access, quality, and value to our members."

Industry Context

The healthcare industry is undergoing significant regulatory changes with the enactment of the One Big Beautiful Bill Act (OBBBA), which introduces Medicaid work-requirement pilots and stricter provider-tax rules. This could lead to reductions in patient populations and managed care enrollees for companies operating in federal healthcare programs. Astrana Health's strategic acquisition of Prospect Medical Holdings, Inc. and its focus on value-based care arrangements position it to adapt to these changes by expanding its provider network and integrated healthcare delivery platform, aiming for cost-effective, high-quality care. The company's diversified footprint and strong Medicaid performance are highlighted as advantages in this evolving regulatory landscape.

Legal Proceedings

• Ongoing arbitration proceeding with a provider associated with CFC Health Plan, Inc. (CFC HP), initiated around October 23, 2023, alleging breach of contract and fraud related to purported failure to pay for services.
• A First Amended Demand for Arbitration was filed around August 8, 2025, further alleging CFC HP never intended to comply with payment terms.
• A charge of $13.0 million was recorded in Q3 2025 in connection with this matter, as a loss is deemed probable.
• The company plans to seek reimbursement for this loss from $14.0 million held in an escrow account from the AHMS acquisition.

Related Party Transactions

• Paid approximately $1.1 million (Q3 2025) and $4.9 million (YTD Sep 2025) to equity method investments for management fee and provider services.
• Incurred rent expenses of approximately $1.2 million (Q3 2025) and $3.7 million (YTD Sep 2025) from properties managed by Allied Pacific Holdings Investment Management, LLC, whose CEO is a board member.
• Operating right-of-use asset balance included $6.6 million and operating lease liabilities included $7.0 million for these properties as of September 30, 2025.
• Investment of $6.0 million in a Simple Agreement for Future Equity (SAFE) with Third Way Health, where one of Astrana's officers is a board member.
• Incurred approximately $0.7 million (Q3 2025) and $3.9 million (YTD Sep 2025) in expenses payable to Third Way Health for call center and credentialing services.
• Agreement with AHMC Healthcare Inc. (AHMC) for hospital and inpatient services; one of Astrana's directors is an officer of AHMC. Revenue from AHMC was $7.3 million (Q3 2025) and $18.6 million (YTD Sep 2025), while expenses to AHMC were $45.9 million (Q3 2025) and $123.9 million (YTD Sep 2025), resulting in a net impact of $(38.6) million (Q3 2025) and $(105.2) million (YTD Sep 2025).
• Risk-sharing agreement with certain AHMC hospitals, recognizing risk pool revenues of $5.2 million (Q3 2025) and $13.1 million (YTD Sep 2025).
• Paid an aggregate of approximately $5.3 million (Q3 2025) and $14.5 million (YTD Sep 2025) to board members for provider services, including amounts to Astrana board members/officers who are also APC board members/officers.

Stakeholder Impact

• Shareholders: Significant revenue growth from acquisitions could be positive, but the sharp decline in net income and increased debt may raise concerns about profitability and leverage. The share repurchase plan indicates management's confidence in stock value.
• Patients/Members: Expansion of the provider network and patient base (over 1.6 million managed patients) suggests increased access to care. Focus on value-based care aims for high-quality, cost-effective services.
• Providers: The Prospect acquisition expanded the provider network by over 11,000, potentially offering more opportunities and resources for affiliated physicians.
• Employees: Increased general and administrative expenses, partly due to supporting operational growth and an increase in the workforce, suggests job stability or growth in certain areas.
• Creditors: Increased long-term debt to over $1 billion and the associated interest expense indicate higher leverage, which creditors will monitor. The security interest granted to lenders in all assets provides some protection.
• Regulatory Authorities: The company is subject to complex healthcare laws and regulations, including DMHC requirements and CMS oversight, and must comply to avoid fines or exclusion from programs. The OBBBA introduces new regulatory challenges.

Next Steps

• Finalize valuation of acquired assets and liabilities for the Prospect acquisition, with potential adjustments to preliminary amounts.
• Finalize purchase price allocation for CHS, subject to working capital adjustments, primarily for medical liabilities and CHS participation in government savings programs for the 2024 performance year.
• Continue discovery and settlement discussions for the CFC Health Plan, Inc. arbitration proceeding.
• Seek reimbursement for the $13.0 million loss from the CFC HP Arbitration through a claim to the escrow funds.
• Evaluate the full downstream effects of the One Big Beautiful Bill Act (OBBBA) on the business.
• Continue to evaluate internal control over financial reporting for the operations of Prospect (currently excluded from assessment).
• Potentially issue common stock, preferred stock, debt securities, and other securities under the current shelf registration statement.

Key Dates

Recommendation

Astrana Health demonstrates strong top-line growth driven by strategic acquisitions, significantly expanding its patient base and provider network. This indicates a robust growth strategy and market presence. However, the substantial decline in net income, increased operating costs, and a notable legal contingency charge raise concerns about profitability and operational efficiency post-acquisition. The increased debt burden and the uncertainties introduced by the OBBBA regulatory changes warrant a cautious approach. While the long-term strategy of value-based care and market expansion is sound, current financial performance and emerging risks suggest a "hold" recommendation until there is clearer evidence of improved net profitability and successful integration of acquired assets, particularly given the significant increase in leverage.

Keywords

Healthcare management, Value-based care, SEC filing, 10-Q, Quarterly report, Financial results, Acquisition, Prospect Medical Holdings, Capitation revenue, Adjusted EBITDA, Medical liabilities, Long-term debt, Risk-bearing organizations, Medicare, Medicaid, Corporate practice of medicine, Regulatory risk, OBBBA, Interest rate swap, California, Provider network, Patient management, Integrated healthcare